Document is current
Any future updates will be listed below
-
Authors
Chaddock, N. J. M.
Crossfield, S. S. R.
Pujades-Rodriguez, M.
Iles, M. M.
Morgan, A. W.
-
Funding
Funding for this research was provided by:
Medical Research Council (MRC) Confidence in Concept award (MC_PC_19042)
MRC Discovery Medicines North Doctoral Training Program
National Institute for Health and Care Research (NIHR) Leeds Biomedical Research Centre
National Institute for Health Research (NIHR) Senior Investigator award
NIHR Leeds Biomedical Research Centre and NIHR Leeds MedTech and In Vitro Diagnostic Evaluation Co-operative
- License Information
-
More Information
Article History
Received: 18 July 2023
Accepted: 9 January 2025
First Online: 15 January 2025
Declarations
:
: None declared for the current manuscript. AWM has received research grant or educational funding or undertaken consultancy for the following pharmaceutical companies on behalf of the University of Leeds in the last 5 years: AstraZeneca, Kiniska Pharmaceuticals, Regeneron, Roche/Chugai, Sanofi and Vifor. MPR is currently employed by Union Chimique Belge (UCB) Biopharma. None declared for MMI, NJMC, or SSRC.
: The study was approved by UK Biobank (project 24559). UK Biobank has ethical approval from the National Research Ethics Committee (REC reference 11/NW/0382), and obtained informed electronic consent from all participants. There was no patient-public involvement in the study, which used non-identifiable data. All methods were performed in accordance with the relevant guidelines and regulations.
